Spreiding schreef op 22 januari 2019 11:28:
15:45 tot 16:30
Michael Osthoff Recombinant human C1 esterase inhibitor (Conestat alfa) in the
prevention of contrast-induced nephropathy in high-risk patients
(PROTECT): a randomized, placebo-controlled, double-blind
single-center trial